Compare Stocks: PMVP, SION, PYXS, and WHWK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PMVP PMV Pharmaceuticals	$1.22	$1.24	$1.02 ▼ $1.88	$65.22M	1.34	285,380 shs	90,893 shs
PYXS Pyxis Oncology	$3.23	$2.83	$1.03 ▼ $5.55	$269.41M	1.31	1.41 million shs	211,989 shs
SION Sionna Therapeutics	$5.87	$33.25	$4.01 ▼ $54.97	$265.38M	1.32	4.60 million shs	783,102 shs
WHWK Whitehawk Therapeutics	$4.62	$4.26	$1.76 ▼ $5.49	$263.39M	0.76	357,753 shs	97,041 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PMVP PMV Pharmaceuticals	0.00%	-8.27%	+9.91%	-0.81%	-12.86%
PYXS Pyxis Oncology	0.00%	+4.87%	+21.89%	+80.45%	+152.34%
SION Sionna Therapeutics	0.00%	+10.96%	-87.55%	-85.65%	-76.16%
WHWK Whitehawk Therapeutics	0.00%	-2.33%	+20.00%	+2.90%	+155.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PMVP PMV Pharmaceuticals	$1.22	$1.24	$1.02 ▼ $1.88	$65.22M	1.34	285,380 shs	90,893 shs
PYXS Pyxis Oncology	$3.23	$2.83	$1.03 ▼ $5.55	$269.41M	1.31	1.41 million shs	211,989 shs
SION Sionna Therapeutics	$5.87	$33.25	$4.01 ▼ $54.97	$265.38M	1.32	4.60 million shs	783,102 shs
WHWK Whitehawk Therapeutics	$4.62	$4.26	$1.76 ▼ $5.49	$263.39M	0.76	357,753 shs	97,041 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PMVP PMV Pharmaceuticals	0.00%	-8.27%	+9.91%	-0.81%	-12.86%
PYXS Pyxis Oncology	0.00%	+4.87%	+21.89%	+80.45%	+152.34%
SION Sionna Therapeutics	0.00%	+10.96%	-87.55%	-85.65%	-76.16%
WHWK Whitehawk Therapeutics	0.00%	-2.33%	+20.00%	+2.90%	+155.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PMVP PMV Pharmaceuticals	2.75	Moderate Buy	$4.00	227.87% Upside
PYXS Pyxis Oncology	2.70	Moderate Buy	$7.50	132.20% Upside
SION Sionna Therapeutics	2.00	Hold	$42.22	619.29% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	77.49% Upside

Current Analyst Ratings Breakdown

Latest PMVP, SION, PYXS, and WHWK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
8/12/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	SION Sionna Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/10/2026	SION Sionna Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/10/2026	SION Sionna Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Sector Perform	$5.00
8/10/2026	SION Sionna Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$5.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.97 per share	N/A
PYXS Pyxis Oncology	$11.04M	24.41	N/A	N/A	$0.86 per share	3.76
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$6.88 per share	N/A
WHWK Whitehawk Therapeutics	$7.14M	36.89	N/A	N/A	$2.89 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PMVP PMV Pharmaceuticals	-$77.74M	-$1.42	N/A	N/A	N/A	N/A	-78.11%	-70.13%	11/11/2026 (Estimated)
PYXS Pyxis Oncology	-$79.62M	-$1.41	N/A	N/A	N/A	N/A	-215.23%	-112.19%	11/2/2026 (Estimated)
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest PMVP, SION, PYXS, and WHWK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/13/2026	Q2 2026	PYXS Pyxis Oncology	-$0.35	-$0.40	-$0.05	-$0.40	$0.03 million	N/A
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PMVP PMV Pharmaceuticals	N/A	7.70	7.70
PYXS Pyxis Oncology	N/A	1.34	1.34
SION Sionna Therapeutics	N/A	20.05	20.05
WHWK Whitehawk Therapeutics	N/A	17.38	17.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PMVP PMV Pharmaceuticals	90.20%
PYXS Pyxis Oncology	39.07%
SION Sionna Therapeutics	N/A
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
PMVP PMV Pharmaceuticals	10.15%
PYXS Pyxis Oncology	5.70%
SION Sionna Therapeutics	5.10%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PMVP PMV Pharmaceuticals	50	53.46 million	48.03 million	Optionable
PYXS Pyxis Oncology	60	83.41 million	78.65 million	Optionable
SION Sionna Therapeutics	35	45.21 million	42.91 million	N/A
WHWK Whitehawk Therapeutics	21	57.01 million	28.56 million	N/A

PMVP, SION, PYXS, and WHWK Headlines

Recent News About These Companies

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

August 28 at 1:01 PM | zacks.com

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

August 26, 2026 | zacks.com

1,341,394 Shares in Whitehawk Therapeutics, Inc. $WHWK Bought by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives $8.20 Consensus PT from Brokerages

August 24, 2026 | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 19, 2026 | marketbeat.com

Whitehawk Therapeutics Inc WHWK

August 14, 2026 | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

August 8, 2026 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 6, 2026 | marketbeat.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

Whitehawk Therapeutics Presents Realâ€‘World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | prnewswire.com

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

May 28, 2026 | prnewswire.com

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

May 21, 2026 | finance.yahoo.com

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

May 21, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

May 20, 2026 | prnewswire.com

Whitehawk Therapeutics officer Ball sells $201k in stock

May 18, 2026 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PMVP, SION, PYXS, and WHWK Company Descriptions

PMV Pharmaceuticals NASDAQ:PMVP

$1.22 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Pyxis Oncology NASDAQ:PYXS

$3.23 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Sionna Therapeutics NASDAQ:SION

$5.87 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

Whitehawk Therapeutics NASDAQ:WHWK

$4.62 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMVP, SION, PYXS, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMVP, SION, PYXS, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMVP, SION, PYXS, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PMVP, SION, PYXS, and WHWK Company Descriptions

PMV Pharmaceuticals NASDAQ:PMVP

Pyxis Oncology NASDAQ:PYXS

Sionna Therapeutics NASDAQ:SION

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMVP, SION, PYXS, and WHWK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMVP, SION, PYXS, and WHWK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMVP, SION, PYXS, and WHWK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PMVP, SION, PYXS, and WHWK Company Descriptions

PMV Pharmaceuticals NASDAQ:PMVP

Pyxis Oncology NASDAQ:PYXS

Sionna Therapeutics NASDAQ:SION

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools